Fellowship · Seattle, WA
Sponsored by University of Washington School of Medicine
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
Kidney international · 2022 · 544 citations · Charles Alpers
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet (London, England) · 2023 · 246 citations · Charles Alpers
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet (London, England) · 2023 · 193 citations · Charles Alpers
Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates.
JAMA surgery · 2021 · 142 citations · Charles Alpers
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
The New England journal of medicine · 2023 · 97 citations · Charles Alpers
Rationale and design of the Kidney Precision Medicine Project.
Kidney international · 2021 · 161 citations · Charles Alpers
Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria.
American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021 · 148 citations · Shreeram Akilesh, Charles Alpers, Behzad Najafian, Roberto Nicosia
Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis.
Nature communications · 2024 · 59 citations · Roberto Nicosia